ASH 2018 | Tabelecleucel for treating EBV associated PTLD
Dietmar Berger
• 2 Dec 2018
From the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dietmar Berger, MD, PhD, of Atara Biotherapeutics, San Francisco, CA., outlines the focus on off-the-shelf, next-generation allogeneic T-cell immunotherapies including tabelecleucel for treating Epstein–Barr virus (EBV) associated post-transplant lymphoproliferative disorder (PTLD), which has received FDA breakthrough and EMA PRIME designation. Dr Berger also discusses the issues with current CAR T-cell therapy approaches and how by utilising novel co-stimulatory domains, can lead to prolonged response to CAR T-cell therapy.
